US05360L4032 - Common Stock
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024...
ATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ:ATXI) just reported results for the first quarter o...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) --...
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
These stocks are gapping in today's session
Curious about the stocks that are showing activity before the opening bell on Monday?
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ:ATXI) just reported results for the fourth quarter ...
ATXI stock results show that Avenue Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - ...
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure...
-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg...
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused...
MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused...
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!